Vietnam Still Plagued by Sex-Selective Abortions
By Thao Vi - An Dien,
Thanh Nien News
| 09. 23. 2014
Untitled Document
“We are startled by the sex ratios at birth in some communes in the Red River Delta, which were up to 150 boys per 100 girls, during a recent visit,” Deputy Health Minister Nguyen Viet Tien said at a press briefing in Hanoi on Tuesday.
The country’s ratio fell lower -- 113.8 boys per 100 girls than last year. Still, the figure represents a sharp increase from 106.2 boys per 100 girls in 2000 and enough to cause policymakers headaches.
According to an official projection, between 2.3 and 4.3 million men won't be able to find wives by 2050.
Worse still, a scarcity of women would increase pressure for them to marry at a younger age and perhaps drop out of school to do so, the United Nations Population Fund (UNFPA) said in a statement released on Tuesday.
In addition, there may be a rising demand for sex work; and trafficking networks may also expand in response to the imbalance, UNFPA warned.
Nguyen Van Tan, director of the General Office for Population and Family Planning, said that one...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...